Bone marrow aspirates and Jamshidi biopsies were taken from the same posterior iliac crest under local anesthesia. A quantity of 0.5-I ml of marrow was aspirated into a 10-mI syringe containing 0.1 ml preservative-free heparin (1000 
Clinical Application
In order to measure treatment-induced cytoreduction in the bone marrow, BMC and BMBC/cu mm BM were monitored in patients with acute nonlymphocytic leukemia (ANLL) who were previously untreated or had relapsed. They received chemotherapy with daunorubicin (DNR), cytosine arabinoside (ARA-C), and 6-thioguanine (6-TG) in combination (DAT).
Other patients with end-stage acute leukemias and non-Hodgkin's lymphomas with bone marrow involvement were followed during phase I and II studies of highdose thymidine (TdR).
High-dose thymidine therapy.
In 4 patients TdR was administered by continuous infusion over a period of I 8-28 days at a dose of 140-240 g/sq m/day by which mM serum levels were maintained.'5 BMC and BMBC/cu mm BM were determined before, at least twice during, and at the end of the TdR infusion.
DA T therapy.
Eleven previously untreated patients and 5 others who had prior chemotherapy or were in relapse of ANLL received a 5-day course of combination chemotherapy consisting of: DNR 60 mg/sq rn/day on days I, 2, and 3; ARA-C 200 mg/sq rn/day from day 1 to 5 by contindous infusion after an initial loading dose of 25 mg iv.; and 6-IG 200 mg/sq rn/day from day 1 to i6 BMC and BMBC/cu mm BM were measured before treatment and on the second and fifth day of therapy.
In 9 patients treated with either DAT or TdR, aspirates were performed in duplicate to test the reproducibility of the quantitation procedure.
The two specimens differed in aspirated volume by a factor of 2 or more and were obtained from different sites within the same anesthetized area.
RESULTS
The described quantitation procedure was applied to a total of 65 sets of blood, aspiration, and biopsy specimens.
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